Science Explorer Back to mapMap
Discussion
Company · Doylestown · United States

OnCore Biopharma (United States)

oncorebiopharma.comROR OpenAlex
Research works
2
fractional, all time
Citations
73
36.5 per fractional work
Top-10% rate
0.0%
all institutions 10.0%
OnCore Biopharma (United States)

Not ranked overall: OnCore Biopharma (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does OnCore Biopharma (United States) work in?

In all years, 85% of research at OnCore Biopharma (United States) is in Health Sciences, 15% in Life Sciences. Its largest fields are Medicine (85%), Biochemistry, Genetics and Molecular Biology (15%). It does 1.4× the world's share of Health Sciences.

Health Sciences: 2 fractional works · 85.0% of its workMedicine: 2 fractional works · 85.0% of its workLife Sciences: 0 fractional works · 15.0% of its workBiochemistry, Genetics and Molecular Biology: 0 fractional works · 15.0% of its workALL ITS WORKOnCore Biopharma(United States)2fractional works, all years
Life Sciences15%Health Sciences85%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 2 domains and 2 fields, with their numbers
    1. Medicine285.0%
    1. Biochemistry, Genetics and Molecular Biology015.0%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from OnCore Biopharma (United States)?

The most cited paper from OnCore Biopharma (United States) is "Nucleotide Prodrugs for the Treatment of HCV Infection" (Michael J. Sofia, 2013), with 50 citations. Next come "Beyond sofosbuvir: What opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?" (44) and "Nucleosides and Nucleotides for the Treatment of Viral Diseases" (4).

Most cited papers
#PaperReleasedCitations
1 Nucleotide Prodrugs for the Treatment of HCV Infection Michael J. Sofia · Advances in pharmacology Book chapter 2013 50
2 Beyond sofosbuvir: What opportunity exists for a better nucleoside/nucleotide to treat hepatitis C? Michael J. Sofia · Antiviral Research May 2014 44
3 Nucleosides and Nucleotides for the Treatment of Viral Diseases Michael J. Sofia · Annual reports in medicinal chemistry Book chapter 2014 4
All 3 most cited papers, with filters and sorting

Which research topics does OnCore Biopharma (United States) publish most on?

By volume: Hepatitis C virus research, HIV/AIDS drug development and treatment, Hepatitis B Virus Studies and Biochemical and Molecular Research.

Hepatitis C virus research1Hepatitis C virus research: 1 fractional worksHIV/AIDS drug developmen…1HIV/AIDS drug development and treatment: 1 fractional worksHepatitis B Virus Studies0Hepatitis B Virus Studies: 0 fractional worksBiochemical and Molecula…0Biochemical and Molecular Research: 0 fractional works
HepatologyInfectious DiseasesEpidemiologyMolecular Biology

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Hepatitis C virus research Hepatology 1 works
  2. 2 HIV/AIDS drug development and treatment Infectious Diseases 1 works
  3. 3 Hepatitis B Virus Studies Epidemiology 0 works
  4. 4 Biochemical and Molecular Research Molecular Biology 0 works

Other research institutions in Doylestown

All research institutions in Doylestown

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about OnCore Biopharma (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.